Fig. 3 | Signal Transduction and Targeted Therapy

Fig. 3

From: Clinical utility of PDX cohorts to reveal biomarkers of intrinsic resistance and clonal architecture changes underlying acquired resistance to cetuximab in HNSCC

Fig. 3

Identification of predictive biomarkers for cetuximab resistance in an independent PDX cohort. a Waterfall plot of cetuximab response in the validation PDX cohort, defined as the tumor volume change compared with tumor volume at baseline after 3 weeks from treatment started (n = 61). Dotted lines indicate the cutoff values for arbitrarily defined categories of therapy response: mPD, mSD, mPR, and mCR are shaded in dark orange, light purple, light orange, and dark brown, respectively. The pie chart shows the distribution (as proportions) of the different cetuximab-response groups (n = 61). b Receiver operating characteristic (ROC) curves of discovery cohort measured by RNA sequencing of SIX2, PARP3, KLF9, and PODXL2 in distinguishing the sensitive group and the intrinsic resistance group. c The ROC curves of the validation cohort measured by real-time qPCR of SIX2, PARP3, KLF9, and PODXL2 in distinguishing the relatively sensitive group and the resistance group. d CNV profiles of intrinsic resistance and relatively sensitive PDX samples in the validation PCT. Each sample ID is denoted by the PDX model ID

Back to article page